|
|
|
|
|
|
|
|
|
The Wright Reports site is no longer hosted or operated by Manta. Please review
the following:
1. You have been redirected to CorporateInformation.com where you can view
Snapshot reports or purchase Wright reports or subscriptions of your choosing.
2. If you were previously linking to Wright Reports please change your links to
www.corporateinformation.com
3. If you are a paid subscriber with an active subscription please continue on
to the member site:
http://member.corporateinformation.com/home.asp
4. For additional information related to CorporateInformation.com please contact
help@corporateinformation.com, Contact phone nr to be provided later)
|
|
|
|
|
|
 |
|
|
|
|
|
|
 |
|
Pharmos Corporation
Company Snapshot
|
|
Business Description:
Pharmos Corporation operates in the Pharmaceutical preparations sector. Pharmos Corporation (Pharmos) is a biopharmaceutical company. Pharmos discovers and develops therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on pain/inflammation, and autoimmune disorders. The Company's product, Dextofisopam, is used for the treatment of irritable bowel syndrome (IBS). During the year ended December 31, 2010, the Company conducted minimal research and development activity. In May 2010, the voluntary liquidation of the Company's subsidiary in Israel, Pharmos Ltd. was completed. The Company's primary focus is on the development and partnering of Dextofisopam. The Company owns the rights to both R and S Tofisopam. Dextofisopam is the R enantiomer of racemic tofisopam and is developed for IBS. During 2010, the Company examined the data from earlier Phase I studies using S-Tofisopam.
|
|
| |
|
| |
|
| |
|
|
|
|
|
|
|
|
| |
| |
Stock Data: |
Recent Stock Performance: |
|
| |
Current Price (2/10/2012):
.08
(Figures in
U.S. Dollars) |
|
1 Week |
-13.8% |
|
13 Weeks |
7.1% |
|
|
|
|
|
|
|
|
|
4 Weeks |
-31.8% |
|
52 Weeks |
-7.4% |
|
|
|
| |
| |
Pharmos Corporation
Key Data: |
|
|
|
| |
Ticker: |
PARS |
Country: |
UNITED STATES |
| |
|
| |
Exchanges: |
OTC |
Major Industry: |
Drugs, Cosmetics & Health Care |
| |
|
| |
|
|
Sub Industry: |
Ethical Drug Manufacturers |
| |
|
| |
2001
Sales |
4,298,000
(Year Ending Jan 2002). |
Employees: |
2 |
| |
|
| |
Currency: |
U.S. Dollars |
Market Cap: |
4,490,954 |
| |
|
| |
Fiscal Yr Ends: |
December |
Shares Outstanding: |
59,879,391 |
| |
|
| |
Share Type: |
Common |
Closely Held Shares: |
35,911,877 |
|
| |
|
| |
| |
|
|
|
CorporateInformation® website and selected data Copyright © 2000 -
by The Winthrop Corporation. All Rights Reserved. Except for quotations by established
news media, no pages on this site may be reproduced, stored in a retrieval system,
or transmitted for commercial purposes, in any form or by any means, electronic,
mechanical, photocopying, recording, or otherwise without prior written permission.
Information is believed reliable, but accuracy, completeness and opinions are not
guaranteed.
|
|
|
|
|